Ofatumumab and CLL

Ofatumumab plus chlorambucil has been approved in the USA as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who cannot receive fludarabine-based therapy.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has also approved the combination of ofatumumab plus chlorambucil or bendamustine in patients with CLL who have not received prior therapy and who cannot receive fludarbine-based therapy. For more information, click here to read the full article, or on the PDF below to read the European approval.

icon Ofatumumab_CHMP_EMA (63.05 kB)

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.